Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2026 · third_quarter · Q3
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, "Most Favored Nation" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549. Generally raising awareness of vaccine efficacy. Providing comments to Senate Finance on ways to lower health care costs. Providing comments to Senate HELP on the 340B program. Providing comments to CMS on the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway.
Source: Senate LDA
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patients Against PBM Abuses Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Protecting Patients Against PBM Abuses Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patients Against PBM Abuses Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
ORPHAN Cures Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
ORPHAN Cures Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
ORPHAN Cures Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
ORPHAN Cures Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Maintaining Investments in New Innovation Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Maintaining Investments in New Innovation Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Maintaining Investments in New Innovation Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
DRUG Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
DRUG Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
DRUG Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
DRUG Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
SMART Prices Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Treat and Reduce Obesity Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Cameron’s Law
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
VALID Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
PASTEUR Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
ORPHAN Cures Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
DRUG Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Saving Access to Laboratory Services Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
SMART Prices Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
SMART Prices Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
SMART Prices Act
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
PASTEUR Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
Prescription Information Modernization Act of 2023
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
PASTEUR Act of 2021
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage.
PASTEUR Act of 2021
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.
PASTEUR Act of 2021
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act
PASTEUR Act of 2021
Client: HEALTHCARE INSTITUTE OF NEW JERSEY · Firm: HEALTHCARE INSTITUTE OF NEW JERSEY
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2026 · second_quarter · Q2
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, "Most Favored Nation" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549. Generally raising awareness of vaccine efficacy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2026 · first_quarter · Q1
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, "Most Favored Nation" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2025 · fourth_quarter · Q4
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information (in the previous Congress, H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the ORPHAN CURES Act (H.R. 946). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2025 · third_quarter · Q3
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information (in the previous Congress, H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the ORPHAN CURES Act (H.R. 946). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2025 · second_quarter · Q2
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information (in the previous Congress, H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the ORPHAN CURES Act (H.R. 946). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD).
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2025 · first_quarter · Q1
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information (in the previous Congress, H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the ORPHAN CURES Act (H.R. 946). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2024 · fourth_quarter · Q4
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2024 · third_quarter · Q3
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Supporting CMS proposed rule, CMS-1809-P, to include separate payment for diagnostic radiopharmaceuticals in CY2025.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2024 · second_quarter · Q2
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880). Supporting the PASTEUR Act (H.R. 2940 and S. 1355). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 5547). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174).
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2024 · first_quarter · Q1
Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2023 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2023 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2023 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2023 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act (S. 2076 and H.R. 3932 in the previous Congress). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 8188 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 4128 in the previous Congress). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2022 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2022 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2022 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2022 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2021 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2021 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2021 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (S. 1712 and H.R. 4100 in the previous Congress; yet to be reintroduced). Supporting the PASTEUR Act (S. 4760 and H.R. 8920 in the previous Congress; reintroduced in June, not yet assigned bill numbers). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2021 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (S. 1712 and H.R. 4100 in the previous Congress; yet to be reintroduced). Supporting the PASTEUR Act (S. 4760 and H.R. 8920 in the previous Congress; yet to be reintroduced). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2021 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (S. 1712 and H.R. 4100 in the previous Congress; yet to be reintroduced). Supporting the PASTEUR Act (S. 4760 and H.R. 8920 in the previous Congress; yet to be reintroduced). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2020 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2020 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2020 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2020 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2019 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting H.R. 2207, the Protect Medical Innovation Act Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2019 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting H.R. 2207, the Protect Medical Innovation Act Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2019 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2019 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the Manufacturing Extension Program (MEP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2018 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff Supporting changes to the America Invents Act to prevent double-jeopardy of patent challenges under the inter partes review process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2018 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff Supporting changes to the America Invents Act to prevent double-jeopardy of patent challenges under the inter partes review process.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2018 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Supporting changes to Medicare Part D's coverage gap liability assignment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2018 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Supporting the repeal of the Independent Payment Advisory Board Opposing the CREATES Act Opposing the provision within the continuing resolution which shifted Medicare Part D coverage gap liability Supporting the inclusion of a provision in the omnibus spending package which shifted Medicare Part D coverage gap liability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2017 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Supporting the repeal of the Independent Payment Advisory Board, specifically HR 849 and S 251.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2017 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Supporting improvements to the FDA's medical device inspection process, specifically S. 404 and H 1736 Supporting the OPEN ACT, HR. 1223 and companion legislation in the Senate to be introduced Opposing S. 771 and HR 1776. Supporting the repeal of the Independent Payment Advisory Board, specifically HR 849 and S 251.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2017 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Opposing the importation of medicines, specifically HR 1245 and S. 469 Supporting improvements to the FDA's medical device inspection process, specifically S. 404 and H 1736 Supporting the OPEN ACT, HR. 1223 and companion legislation in the Senate to be introduced Opposing S. 771 and HR 1776. Supporting the repeal of the Independent Payment Advisory Board, specifically HR 849 and S 251.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2017 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors Opposing the imposition of price controls in the Medicare program Generally supporting intellectual property rights Generally supporting the full repeal of the medical device excise tax Opposing the importation of medicines, specifically HR 1245 and S. 469 Supporting improvements to the FDA's medical device inspection process, specifically S. 404 Supporting the OPEN ACT, HR. 1223 and companion legislation in the Senate to be introduced
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2016 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting 21st Century Cures initiative Opposing changes to the Medicare Part B program, specifically the Centers for Medicare & Medicaid Services (CMS) March 8, 2016 proposed rule. Opposing CBO's current system of scoring CMMI demonstration projects. Generally commenting on FDA's recommendations for the reauthorization of the Medical Device User Fee Amendments (MDUFA) for fiscal years 2018 through 2022.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2016 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting HR 6, the 21st Century Cures initiative, and various Senate companion bills. Opposing changes to the Medicare Part B program, specifically the Centers for Medicare & Medicaid Services (CMS) March 8, 2016 proposed rule. Opposing CBO's current system of scoring CMMI demonstration projects. Generally commenting on FDA prescription requirements for compounded drug products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2016 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting HR 1078, the FDA Safety over Sequestration Act. Supporting HR 6, the 21st Century Cures initiative, and various Senate companion bills. Opposing changes to the Medicare Part B program, specifically the Centers for Medicare & Medicaid Services (CMS) March 8, 2016 proposed rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2016 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Generally supporting the full repeal of the medical device excise tax. Supporting HR 1078, the FDA Safety over Sequestration Act. Supporting HR 6, the 21st Century Cures initiative. Opposing changes to the Medicare Part B program, specifically the Centers for Medicare & Medicaid Services (CMS) March 8, 2016 proposed rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2015 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Supporting HR 1078, the FDA Safety over Sequestration Act. Supporting HR 6, the House Energy and Commerce Committee's 21st Century Cures initiative Opposing HR 9, the Innovation Act (patent reform) Supporting HR 160, the Protect Medical Innovation Act (repeal of the medical device excise tax) Supporting HR 2029, the Consolidated Appropriations Act 2016
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2015 · third_quarter · Q3
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Supporting HR 1078, the FDA Safety over Sequestration Act. Opposing Senate Amendment 921 regarding price controls in Medicare Part D. Supporting HR 6, the House Energy and Commerce Committee's 21st Century Cures initiative Opposing HR 9, the Innovation Act (patent reform) Supporting HR 160, the Protect Medical Innovation Act (repeal of the medical device excise tax) Supporting HR 1190, the Protecting Seniors Access to Medicare Act (repeal of the Independent Payment Advisory Board (IPAB))
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2015 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting intellectual property rights. Supporting HR 1078, the FDA Safety over Sequestration Act. Opposing Senate Amendment 921 regarding price controls in Medicare Part D. Supporting HR 6, the House Energy and Commerce Committee's 21st Century Cures initiative Opposing HR 9, the Innovation Act (patent reform) Supporting HR 160, the Protect Medical Innovation Act (repeal of the medical device excise tax) Supporting HR 1190, the Protecting Seniors Access to Medicare Act (repeal of the Independent Payment Advisory Board (IPAB))
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2015 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare program. Generally supporting the delay and repeal of the medical device excise tax. Supporting HR 160, the Protect Medical Innovation Act. Supporting S 149, the Medical Device Access and Innovation Protection Act. Supporting HR 2, the Medicare Access and CHIP Reauthorization Act. Generally supporting intellectual property rights. Supporting HR 1078, the FDA Safety over Sequestration Act. Opposing Senate Amendment 921 regarding price controls in Medicare Part D. Generally supporting the House Energy and Commerce Committee's 21st Century Cures initiative
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2014 · fourth_quarter · Q4
Opposing the imposition of price controls in the Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2014 · third_quarter · Q3
Supported changes to S 1720, the Patent Transparency and Improvement Act, which would strengthen protections against patent infringements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2014 · second_quarter · Q2
Generally supporting intellectual property rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2014 · first_quarter · Q1
Generally supporting intellectual property rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2013 · fourth_quarter · Q4
Generally supporting the delay and repeal of the medical device excise tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2013 · third_quarter · Q3
Generally supporting the delay and repeal of the medical device excise tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2013 · second_quarter · Q2
Promoting awareness of the biopharmaceutical and medical technology sectors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2013 · first_quarter · Q1
Promoting awareness of the biopharmaceutical and medical technology sectors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2012 · fourth_quarter · 4A
Generally supporting the delay and repeal of the medical device excise tax, including HR 436 and S 262.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2012 · fourth_quarter · Q4
Generally supporting the delay and repeal of the medical device excise tax, including HR 436 and S 262.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2012 · third_quarter · Q3
Supporting the repeal of the Independent Payment Advisory Board (IPAB); specifically S 668 and HR 452.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2012 · second_quarter · Q2
Supporting the repeal of the Independent Payment Advisory Board (IPAB); specifically S 668 and HR 452.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2012 · first_quarter · Q1
Generally supporting the repeal of the medical device excise tax, specifically HR 436 and S 262.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · fourth_quarter · Q4
Opposing the imposition of price controls in the Medicare program; specifically, HR 2190 as well as similar proposals offered to the Joint Select Committee on Deficit Reduction.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · third_quarter · Q3
Supporting the repeal of the Independent Payment Advisory Board (IPAB); specifically S 668 and HR 452.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · second_quarter · Q2
Supporting the repeal of the Independent Payment Advisory Board (IPAB); specifically S 668 and HR 452.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · second_quarter · Q2
Supporting reform of the patent system to make it more efficient, equitable and timely; specifically, S23 and HR1249.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2011 · first_quarter · Q1
Promoting the prevention of health care-associated infections through value-based purchasing programs in CMS.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · fourth_quarter · Q4
Promoting awareness of the biopharmaceutical and medical technology sectors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · third_quarter · Q3
promoting awareness of the biopharmaceutical and medical technology sectors promoting awareness of medical devices and their regulatory pathway through the FDA Promoting the prevention of health care associated infections through value based purchasing programs in CMS.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · second_quarter · Q2
promoting awareness of the biopharmaceutical and medical technology sectors promoting awareness of medical devices and their regulatory pathway through the FDA Promoting the prevention of health care associated infections through value based purchasing programs in CMS.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2010 · first_quarter · Q1
promoting awareness of the research-based biopharmaceutical and medical technology sector Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · fourth_quarter · Q4
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act HR 2502 Comparative Effectiveness Research Act of 2009
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · third_quarter · Q3
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · second_quarter · Q2
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Support Eshoo-Barton Pathways to Biosimilars Act HR 1548 Support Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform health care reform- supported open access and choice of plans
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2009 · first_quarter · Q1
Support Eshoo/Barton Pathways to Biosimilars Act Support Kennedy Pathways to Biosimilars Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2008 · fourth_quarter · Q4
Oppose the Medical Device Safety Act of 2008
Promoting understanding of the causes and cost of chronic disease.
Advocating for patent protections in trade bills and in foreign government operations
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2008 · fourth_quarter · RA
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2008 · third_quarter · Q3
Promoting understanding of the causes and cost of chronic disease.
Advocating for patent protections in trade bills and in foreign government operations
Amending the Patent Reform Act of 2008 in the Senate
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2008 · second_quarter · Q2
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
recognizing the importance of biomedical research, diagnostics, and technologies.
promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2008 · first_quarter · Q1
Medicare Reform Package
Pharmaceuticals in the Environment
FY09 Agriculture Appropriations and FY09 Homeland Security Appropriations related to proposals limiting FDA authority to regulate pharmaceutical imports
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2007 · year_end · YY
H.R. 3161; S. 1859-Agriculture Appropriations and H.R. 2638; S.1644-Homeland Security Appropriations related to proposals limiting FDA authority to regulate pharmaceutical imports
To promote understanding of issues around the research based biopharmaceutical and medical device industry
To promote intellectual property protection in all trade agreements- in particular Andean Trade, Thailand, and Brazil.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2007 · year_end · YY
To promote understanding of issues around the research based biopharmaceutical and medical device industry
To promote Medicare Modernization Act and educate members about the program and its success.
To promote intellectual property protection in all trade agreements- in particular Andean Trade, Thailand, and Brazil.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2007 · year_end · YY
H.R. 3161; S. 1859-Agriculture Appropriations and H.R. 2638; S.1644-Homeland Security Appropriations related to proposals limiting FDA authority to regulate pharmaceutical imports
To promote Medicare Modernization Act and educate members about the program and its success.
To promote intellectual property protection in all trade agreements- in particular Andean Trade, Thailand, and Brazil.
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2007 · mid_year · MM
* HR 4 S.3 Medicare Non-Interference FDA Reform Legislation Medical Device User Fees Prescription Drug User Fees REMS SCHIP Children's Health Insurance Legislation
Prescription Drug Imporation/Agricultural Appropriations Legislation
House and Senate Patent Reform Legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2006 · year_end · YY
Agricultural Appropriations-FDA Reimportation
* Medicare Part D implementation Regulating the Reprocessing of Single-Use Medical Devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2006 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2006 · mid_year · RA
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2005 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2005 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2004 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2004 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2003 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2003 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2002 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2002 · year_end · RA
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2002 · year_end · RA
HEALTHCARE INSTITUTE OF NEW JERSEY via HEALTHCARE INSTITUTE OF NEW JERSEY
2002 · mid_year · RR
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Amending the Patent Reform Act of 2008 in the Senate
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
importation in appropriations bills, patent reform, health care reform, pharmaceutcial and medical device pricing, reimbursement issues, Medicare Part D coverage and pricing, corporate tax, trade agreeements, preemption.
Oppose the Medical Device Safety Act of 2008
Advocating on behalf of Medicare Part D open access and encouraging open market access to medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
To promote the better understanding of the pharmaceutical and medical device industry in New Jersey.
Issues relating to importation of prescription drugs and intellectual property protections.
S 1182 Patent Reform Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
To promote Medicare Modernization Act and educate members about the program and its success.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 3161; S. 1859-Agriculture Appropriations and H.R. 2638; S.1644-Homeland Security Appropriations related to proposals limiting FDA authority to regulate pharmaceutical imports
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
To promote understanding of issues around the research based biopharmaceutical and medical device industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE